Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?
- 30 August 2020
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 24 (10) , 1047-1059
Abstract
Salivary gland cancers (SGCs) consist of a rare family of neoplasms with varying histology and biological behavior. Therapeutic regimens have been relatively unchanged for decades. The recent succe...Keywords
This publication has 105 references indexed in Scilit:
- Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell ActivationThe Journal of Immunology, 2012
- Programmed Death Ligand 2 in Cancer-Induced Immune SuppressionJournal of Immunology Research, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent MannerCancer Cell, 2010
- Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in miceJournal of Clinical Investigation, 2009
- Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinomaCancer, 2008
- Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse ModelClinical Cancer Research, 2008
- Recurrent salivary gland carcinomas treated by surgery with or without intraoperative radiation therapyHead & Neck, 2007
- Stereotactic Radiosurgery as a Salvage Treatment for Recurrent Skull Base Adenoid Cystic CarcinomaStereotactic and Functional Neurosurgery, 2005